Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern

Abstract excerpt

As of October, 2021, SARS-CoV-2 has infected more than 230 million people; promoting roll-out vaccinations could help build herd immunity for the pandemic. However, the waning of antibody in magnitude and decreased protective efficacy in multiple types of vaccines have been reported. Along with the circulating variants to some degree escaping from immune response, these led to the argument of further booster...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to COVID-19 Clinical Research Studies
• Share to Peripheral Neuropathies and Disorders
• Share to SARS-CoV-2 and COVID-19 Research